Effects of Hypericum perforatum extract on rat irritable bowel syndrome

Pharmacognosy Magazine

Volumn 7, Issue 27, 2011, Pages 213-223

  Mozaffari, Shilan ^a,b   Esmaily, Hadi ^c   Rahimi, Roja ^b   Baeeri, Maryam ^b   Sanei, Yara ^a,b   Asadi Shahmirzadi, Azar ^a,b   Salehi Surmaghi, Mohammad Hossein ^a,b   Abdollahi, Mohammad ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hypericum perforatum; irritable bowel syndrome; oxidative stress

Indexed keywords

FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; LOPERAMIDE; MYELOPEROXIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; IMMOBILIZATION STRESS; INTESTINE TRANSIT TIME; IRRITABLE COLON; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; POST HOC ANALYSIS; RAT; STOMACH EMPTYING; TISSUE HOMOGENATE;

EID: 80052747787     PISSN: 09731296     EISSN: 09764062     Source Type: Journal    
DOI: 10.4103/0973-1296.84235     Document Type: Article

References (70)

1. Croghan A, Heitkemper MM. Recognizing and managing patients with irritable bowel syndrome. J Am Acad Nurse Pract 2005;17:51-9.
2. Foxx-Orenstein A. IBS: Review and what's new. Med Gen Med 2006;8:20.
3. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-17. (Pubitemid 36169247)
4. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83. (Pubitemid 34651421)
5. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702. (Pubitemid 38298317)
6. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007;56:203-9.
7. Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-20. (Pubitemid 46440872)
8. Kristjánsson G, Venge P, Wanders A, Lööf L, Hällgren R. Clinical subclinical intestinal inflammation assessed by the mucosal patch technique: Studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut 2004;53:1806-12. (Pubitemid 39556901)
9. Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut 2001;49:743-5. (Pubitemid 33096023)
10. Ponferrada A, Caso JR, Alou L, Colón A, Sevillano D, Moro MA, et al. The role of PPARgamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology 2007;132:1791-803. (Pubitemid 46677934)
11. Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: Role of ATP. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery 2009;3:69-75.
12. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: A meta-analysis of eight randomized, placebocontrolled, 12-week trials. Clin Ther 2008;30:884-901. (Pubitemid 351802282)
13. Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: A meta-analysis of randomized controlled trials. Arch Med Sci 2008;4:71-6. (Pubitemid 351588826)
14. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: A meta-analysis. World J Gastroenterol 2009;15:1548-53.
15. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010;16:547-53.
16. Camilleri M, Kim DY, McKinzie S, Kim HJ, Thomforde GM, Burton DD, et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003;1:111-21. (Pubitemid 37248082)
17. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: A meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008;51: 1775-80.
18. Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: A systematic review and meta-analysis. Arch Med Sci 2010;6:49-55.
19. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:118-27.
20. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. Montvale, NJ: Medical Economics Co.; 1998. p. 719-25.
21. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997;30:129-34.
22. Zou Y, Lu Y, Wei D. Antioxidant activity of a flavonoid-rich extract o Hypericum perforatum L. in vitro. J Agric Food Chem 2004;52:5032-9.
23. Benedí J, Arroyo R, Romero C, Martín-Aragón S, Villar AM. Antioxidant properties and protective effects of a standardized extract of Hypericum perforatum on hydrogen peroxide-induced oxidative damage in PC12 cells. Life Sci 2004;75:1263-76. (Pubitemid 38829351)
24. Zdunic G, Godevac D, Milenkovic M, Vucicevic D, Savikin K, Menkovic N, et al. Evaluation of Hypericum perforatum oil extracts for an anti-inflammatory and gastroprotective activity in rats. Phytother Res 2009;23:1559-64.
25. Savikin K, Dobric S, Tadic V, Zdunic G. Anti-inflammatory activity of ethanol extracts of Hypericum perforatum L., H. barbatum Jacq., H. hirsutum L., H. richeri Vill and H. androsaemum L. in rats. Phytother Res 2007;21:176-80.
26. Czéh B, Müller-Keuker JI, Rygula R, Abumaria N, Hiemke C, Domenici E, et al. Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: Hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 2007;32:1490-1503. (Pubitemid 46920152)
27. Funatsu T, Takeuchi A, Hirata T, Keto Y, Akuzawa S, Sasamata M. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. Eur J Pharmacol 2007;573:190-5. (Pubitemid 47470060)
28. Zamani MJ, Sharifzadeh M, Rezaie A, Mashayekhi F, Abdollahi M. Effects of sildenafil on rat Irritable Bowel Syndrome. Therapy 2005;2:237-42. (Pubitemid 40450566)
29. Hasani P, Yasa N, Vosough-Ghanbari S, Mohammadirad A, Dehghan G, Abdollahi M. In vivo antioxidant potential of teucrium polium, as compared to a-tocopherol. Acta Pharmaceutica 2007;57:123-9. (Pubitemid 46361953)
30. Nakhai LA, Mohammadirad A, Yasa N, Minaie B, Nikfar S, Ghazanfari G, et al. Benefits of Zataria multiflora Boiss in experimental model of mouse inflammatory bowel disease. Evid Based Complement Alternat Med 2007;4:43-50. (Pubitemid 46410877)
31. Astaneie F, Afshari M, Mojtahedi A, Mostafalou S, Zamani MJ, Larijani B, et al. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res 2005;36: 376-81. (Pubitemid 40798392)
32. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 1976;72:248-54.
33. Fukudo S. Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol 2007;42:48-51. (Pubitemid 46140364)
34. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: Plasma cytokines as a potential biomarker̂ Gastroenterology 2006;130:304-11. (Pubitemid 43202030)
35. Ferrier L, Mazelin L, Cenac N, Desreumaux P, Janin A, Emilie D, et al. Stress-induced disruption of colonic epithelial barrier: Role of interferongamma and myosin light chain kinase in mice. Gastroenterology 2003;125:795-804. (Pubitemid 37070697)
36. Gué M, Bonbonne C, Fioramonti J, Moré J, Del Rio-Lachéze C, Coméra C, et al. Stress-induced enhancement of colitis in rats: CRF and arginine vasopressin are not involved. Am J Physiol 1997;272:84-91.
37. Kiliaan AJ, Saunders PR, Bijlsma PB, Berin MC, Taminiau JA, Groot JA, et al. Stress stimulates transepithelial macromolecular uptake in rat jejunum. Am J Physiol 1998;275:1037-44.
38. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009;146:41-6.
39. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94. (Pubitemid 43829995)
40. Pabuçcuoglu A, Konyalioglu S, Bas M, Meral GE. The in vitro effects of Hypericum species on human leukocyte myeloperoxidase activity. J Ethnopharmacol 2003;87:89-92. (Pubitemid 36644978)
41. Menegazzi M, Di Paola R, Mazzon E, Muiá C, Genovese T, Crisafulli C, et al. Hypericum perforatum attenuates the development of carrageenan-induced lung injury in mice. Free Radic Biol Med 2006;40:740-53. (Pubitemid 43327309)
42. Guemei AA, El Din NM, Baraka AM, El Said Darwish I. Do desipramine [10,11-dihydro-5-[3-(methylamino) propyl]- 5H-dibenz[b,f]azepine monohydrochloride] and fluoxetine [N-methyl-3-phenyl-3-[4-(trifluoromethyl) phenoxy]-propan-1- amine] ameliorate the extent of colonic damage induced by acetic acid in rats? J Pharmacol Exp Ther 2008;327:846-50.
43. Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M. Long-term antidepressant administration alters corticotropinreleasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Investig 1991;87:831-7.
44. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:159-66. (Pubitemid 24220591)
45. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrheapredominant irritable bowel syndrome. Dig Dis Sci 1995;40:86-95.
46. Butterweck V, Winterhoff H, Herkenham M. St John's wort, hypericin, and imipramine: A comparative analysis of mRNA levels in brain areas involved in HPA axis control following shortterm and long-term administration in normal and stressed rats. Mol Psychiatry 2001;6:547-64. (Pubitemid 32772564)
47. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44:400-6. (Pubitemid 29119338)
48. Gwee KA, Graham JC, McKendrick MW, Collins SM, Marshall JS, Walters SJ, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996;347:150-3. (Pubitemid 26025154)
49. Van der Veek PP, van den BM, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin- 10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510-16.
50. O'Sullivan M, Clayton N, Moloney G, Bountra C, Crotty P, Buckley M, et al. Increased iNOS expression in irritable bowel syndrome (IBS) patients with stress related symptoms. Gastroenterology 2003;124:M1642.
51. Ding Y, Lu B, Chen D, Meng L, Shen Y, Chen S. Proteomic analysis of colonic mucosa in a rat model of irritable bowel syndrome. Proteomics 2010;10:2620-30.
52. Raso GM, Pacilio M, Di Carlo G, Esposito E, Pinto L, Meli R. Invivo and in-vitro anti-inflammatory effect of Echinacea purpurea and Hypericum perforatum. J Pharm Pharmacol 2002;54: 1379-83. (Pubitemid 35174184)
53. Nakade Y, Tsuchida D, Fukuda H, Iwa M, Pappas TN, Takahashi T. Restraint stress delays solid gastric emptying via a central CRF and peripheral sympathetic neuron in rats. Am J Physiol Regul Integr Comp Physiol 2005;288:427-32.
54. Martinez V, Barquist E, Rivier J, Taché Y. Central CRF inhibits gastric emptying of a nutrient solid meal in rats: The role of CRF2 receptors. Am J Physiol 1998;274:965-70.
55. Kalin NH, Takahashi LK, Chen FL. Restraint stress increases corticotropin-releasing hormone mRNA content in the amygdala and paraventricular nucleus. Brain Res 1994;656:182-6. (Pubitemid 24263046)
56. Ochi M, Tominaga K, Tanaka F, Tanigawa T, Shiba M, Watanabe T, et al. Effect of chronic stress on gastric emptying and plasma ghrelin levels in rats. Life Sci 2008;82:862-68.
57. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001;96: 1499-506. (Pubitemid 32455081)
58. Nakade Y, Fukuda H, Iwa M, Tsukamoto K, Yanagi H, Yamamura T, et al. Restraint stress stimulates colonic motility via centralv corticotropin- releasing factor and peripheral 5-HT3 receptors in conscious rats. Am J Physio Gastrointest Liver Physiol 2007;292:1037-44.
59. Lenz HJ, Burlage M, Raedler A, Greten H. Central nervous system effects of corticotropin-releasing factor on gastrointestinal transit in the rat. Gastroenterology 1988;94:598-602. (Pubitemid 18073518)
60. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 2000;97:6079-84. (Pubitemid 30367526)
61. Kalin NH, Shelton SE, Kraemer GW, McKinney WT. Associated endocrine, physiological and behavioral changes in rhesus monkeys after intravenous corticotropin-releasing factor administration. Peptides 1983;4:211-5. (Pubitemid 13047886)
62. Simmen U, Burkard W, Berger K, Schaffner W, Lundstrom K. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system. J Recept Signal Transduct Res 1999;19:59-74. (Pubitemid 29152175)
63. Butterweck V, Schmidt M. St: John's wort: Role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr 2007;157:356-61. (Pubitemid 47356264)
64. Wan H, Chen Y. Effects of antidepressive treatment of Saint John's wort extract related to autonomic nervous function in women with irritable bowel syndrome. Int J Psychiatry Med 2010;40:45-56.
65. Saito YA, Rey E, Almazar-Elder AE, Harmsen WS, Zinsmeister AR, Locke GR, et al. A randomized, double-blind, placebocontrolled trial of St John's wort for treating irritable bowel syndrome. Am J Gastroenterol 2010;105:170-7.
66. Melzer M, Fuhrken D, Kolkmann R. Hyperforin im Johanniskraut. Hauptwirkstoff oder nur Leitsubstanz? Dtsch Apoth Ztg 1998;13:4754-60.
67. Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H. Step by step removal of hyperforin and hypericin: Activity profile of different Hypericum preparations in behavioral models. Life Sci 2003;73:627-39. (Pubitemid 36589040)
68. Butterweck V, Jürgenliemk G, Nahrstedt A, Winterhoff H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med 2000;66:3-6. (Pubitemid 30097270)
69. Mozaffari S, Rahimi R, Abdollahi M. Implications of melatonin therapy in irritable bowel syndrome: A systematic review. Curr Pharm Des 2010;16:3646-55.
70. Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies. Dig Dis Sci 2009;54:471-80.